Skip to content
Acting Auditions – Lifestyle
Author:
NanoViricides
High-Performing Provider Designation Offers Health Plan Members Greater Choice
July 28, 2026
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
July 24, 2026
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
July 22, 2026
Research Analyst Report on NanoViricides Rates Company “Outperform”; Separately, A “Fireside Chat” Interview of the Company’s President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
July 8, 2026
US FDA Has Granted A “Rare Pediatric Disease Drug” Designation for NV-387 As A Treatment for Measles – Enables Priority Review Voucher
June 29, 2026
New Landscape Review from Johns Hopkins and American Specialty Health Highlights Growing Role of Physical and Occupational Therapy in Workforce Health
June 23, 2026
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment – with Superior Oral Administration and Escape Resistance Features Over Antibodies
June 8, 2026
American Specialty Health Expands Network Capabilities by Including Home-Based and Mobile PT/OT Services
May 26, 2026
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering
May 19, 2026
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
May 15, 2026
1
2
Next Page
→